<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848029</url>
  </required_header>
  <id_info>
    <org_study_id>V87P12</org_study_id>
    <secondary_id>2008-003008-72</secondary_id>
    <nct_id>NCT00848029</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The present study will evaluate the immunogenicity, safety and immunogenicity of two doses of
      monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a
      surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of antibody response to a monovalent inactivated influenza vaccine adjuvanted with MF59 and uses a surface antigen from a potential pandemic homologous virus strain candidate (H5N1).</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety of the monovalent inactivated influenza vaccine that is adjuvanted with MF59C.1 (MF59) and uses a surface antigen from a potential pandemic virus strain candidate (H5N1) in Adult Subjects.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Pre-pandemic Influenza Vaccine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent inactivated influenza vaccine</intervention_name>
    <description>Two doses of monovalent inactivated influenza adjuvanted vaccine</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 to 60 years of age who are mentally competent and who have signed an
             informed consent form after having received a detailed explanation of the study
             protocol;

          -  In good health as determined by:

               -  Medical history,

               -  Physical examination,

               -  Clinical judgment of the Investigator;

          -  Able to understand and comply with all study procedures and to complete study diaries,
             can be contacted, and will be available for all study visits.

        Exclusion Criteria:

          -  Previous receipt of any H5 vaccine;

          -  Receipt of another investigational agent within 4 weeks, or before completion of the
             safety follow-up period in another study, whichever is longer, prior to enrollment and
             unwilling to refuse participation in another clinical study through the end of the
             study;

          -  Experienced any acute disease or infection requiring systemic antibiotic or antiviral
             therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable)
             within the past 7 days;

          -  Experienced fever (defined as axillary temperature 38.0Â°C) within 3 days prior to
             Visit 1;

          -  Pregnant or breastfeeding;

          -  Females of childbearing potential who refuse to use an acceptable method of birth
             control for the duration of the study. Adequate contraception is defined as hormonal
             (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g.,
             condom with spermicide or diaphragm with spermicide), intrauterine device (e.g., IUD),
             or monogamous relationship with vasectomized partner who has been vasectomized for 6
             months or more prior to the subject's study entry;

          -  Any serious disease, such as:

               -  cancer,

               -  Autoimmune disease,

               -  diabetes mellitus,

               -  chronic pulmonary disease,

               -  acute or progressive hepatic disease,

               -  acute or progressive renal disease;

          -  Surgery planned during the study period;

          -  Bleeding diathesis;

          -  Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,
             neomycin or polymyxin or any other component of the study vaccine;

          -  History of any neurological symptoms or signs following administration of any vaccine,
             or anaphylactic shock following administration of any vaccine;

          -  Known or suspected impairment/alteration of immune function, for example, resulting
             from:

               -  Receipt of immunosuppressive therapy (any corticosteroid therapy

               -  Receipt of immunostimulants,

               -  High risk for developing an immunocompromising disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vaccination and Travel Medicine Centre</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=3441</url>
    <description>Results for V87P12 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin Ther. 2010 Dec;32(13):2186-97. doi: 10.1016/S0149-2918(11)00024-5.</citation>
    <PMID>21316535</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

